These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 9096194)

  • 41. Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents.
    Gradelski E; Kolek B; Bonner DP; Valera L; Minassian B; Fung-Tomc J
    Int J Antimicrob Agents; 2001 Feb; 17(2):103-7. PubMed ID: 11165113
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of flouroquinolone therapy for gram-negative infections within the intensive care unit setting.
    Hassoun A; Eiland E
    Am J Med; 2006 Jun; 119(6):e7. PubMed ID: 16750952
    [No Abstract]   [Full Text] [Related]  

  • 43. [Analysis of distribution and drug resistance of pathogens of burn patients during 9 years].
    Dou Y; Zhang Q
    Zhonghua Shao Shang Za Zhi; 2018 Mar; 34(3):153-159. PubMed ID: 29609277
    [No Abstract]   [Full Text] [Related]  

  • 44. Development of resistant bacteria isolated from dogs with otitis externa or urinary tract infections after exposure to enrofloxacin in vitro.
    Brothers AM; Gibbs PS; Wooley RE
    Vet Ther; 2002; 3(4):493-500. PubMed ID: 12584687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004.
    Lockhart SR; Abramson MA; Beekmann SE; Gallagher G; Riedel S; Diekema DJ; Quinn JP; Doern GV
    J Clin Microbiol; 2007 Oct; 45(10):3352-9. PubMed ID: 17715376
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro susceptibility of nosocomial Pseudomonas aeruginosa, enterobacteriaceae, and staphylococci to ciprofloxacin and ten other broad-spectrum antibiotics.
    Weinstein RA; Nathan C; Delzell D; Kabins SA
    Chemioterapia; 1987 Oct; 6(5):315-8. PubMed ID: 3123078
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging fluoroquinolone-resistance for common clinically important gram-negative bacteria in Taiwan.
    Sheng WH; Chen YC; Wang JT; Chang SC; Luh KT; Hsieh WC
    Diagn Microbiol Infect Dis; 2002 Jun; 43(2):141-7. PubMed ID: 12088622
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
    Cetinkaya E; Coban AY; Durupinar B
    Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
    Demir T; Buyukguclu T
    Int J Infect Dis; 2013 Nov; 17(11):e966-70. PubMed ID: 23742831
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Resistance to fluoroquinolones in Pseudomonas aeruginosa and Klebsiella pneumoniae.
    Rydberg J; Larsson C; Miörner H
    Scand J Infect Dis; 1994; 26(3):317-20. PubMed ID: 7939432
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004].
    Yamaguchi K; Murakami M; Takahashi A; Ishii Y; Iwata M; Itoh K; Oohara T; Watanabe N; Uehara N; Nomura F; Watanabe M; Yasujima M; Kasai T; Kanno H; Aihara M; Suwabe A; Yamahata K; Maesaki S; Hashikita G; Kaku M; Kanemitsu K; Miyake K; Oguri T; Yoshida H; Nishiyama K; Okada J; Tazawa Y; Komatsu M; Nakashima H; Takemura H; Kinoshita S; Okada M; Kobayashi S; Taminato T; Negayama K; Horii T; Murase M; Miyamoto H; Baba H; Kusano N; Mihara E; Ishigo S; Kambe M; Itaha H; Fujita N; Komori T; Ono J; Yoshimura H; Ichiyama S; Maeda S; Hirakata Y; Matsuda J; Yamanaka K; Mutara Y; Saikawa T; Hiramatsu K; Taminato S
    Jpn J Antibiot; 2005 Dec; 58(6):655-89. PubMed ID: 16521347
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antimicrobial resistance patterns of clinical bacterial isolates in southwestern Ethiopia.
    Gebre-Sealsssie S
    Ethiop Med J; 2007 Oct; 45(4):363-70. PubMed ID: 18326346
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Analysis of distribution and drug resistance of pathogens from the wounds of 1 310 thermal burn patients].
    Zhang C; Gong YL; Luo XQ; Liu MX; Peng YZ
    Zhonghua Shao Shang Za Zhi; 2018 Nov; 34(11):802-808. PubMed ID: 30481922
    [No Abstract]   [Full Text] [Related]  

  • 55. [Distribution and drug-resistance of 3 500 gram-negative bacteria in Guangzhou].
    Xiao QZ; Su DH; Jiang JH; Zhong NS
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Feb; 25(2):132-8. PubMed ID: 15698988
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In-vitro activity of four new fluoroquinolones.
    García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
    J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk factors associated with resistance to ciprofloxacin in clinical bacterial isolates from intensive care unit patients.
    Levin PD; Fowler RA; Guest C; Sibbald WJ; Kiss A; Simor AE
    Infect Control Hosp Epidemiol; 2007 Mar; 28(3):331-6. PubMed ID: 17326025
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Increase in the frequency of norfloxacin and ciprofloxacin resistance of bacteria isolated from urine culture].
    Lopes AA; Salgado K; Martinelli R; Rocha H
    Rev Assoc Med Bras (1992); 1998; 44(3):196-200. PubMed ID: 9755547
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
    Cunha BA; Qadri SM; Ueno Y; Walters EA; Domenico P
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.